Safety study of a pneumococcal vaccine in older adults
Part of Infections clinical trials.
This study tests a new pneumococcal vaccine (PCV26) for safety in adults 60 and older. It aims to find out if the vaccine is safe and how the body responds to it.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 60 years or older.
- You have not had a pneumococcal infection or vaccine in the past 3 years.
- You do not have a weakened immune system or a bleeding disorder.
- You are not currently sick with a fever (temperature over 100.4°F) or taking certain medicines like ibuprofen or antihistamines.
- If you are a woman who could become pregnant, you must have a negative pregnancy test and use birth control for at least 28 days after vaccination.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study is looking at how age affects the immune system's response to a pneumococcal vaccine. Researchers want to compare younger and older adults to see if immune cells change with age.
This trial tests a new vaccine designed to protect against 24 types of pneumococcal bacteria (which cause pneumonia and other serious infections). Researchers are checking if it's safe and how well it works in infants, children, and adults.
This trial tests a new 23-valent pneumococcal vaccine to see if it safely protects healthy people against pneumonia and other infections caused by pneumococcal bacteria.
This trial tests if a pneumococcal vaccine (PCV-20) is safe and works well when given to adults during a fever. It may help protect people with certain health conditions from serious pneumococcal infections.
This study tests a new pneumococcal vaccine (PCV15) to see how well it protects against carrying the bacteria that can cause pneumonia. Healthy adults aged 18–50 who have not had a pneumococcal vaccine in the last 5 years may join.
This study tests whether a new pneumococcal vaccine (which protects against a serious bacterial infection) is safe in healthy 2-month-old infants. Researchers will watch for side effects and help protect future babies from pneumococcal disease.
Hear when a new Pneumococcal Diseases trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.